Comparative Pharmacology
Head-to-head clinical analysis: NOXAFIL POWDERMIX KIT versus NYSTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOXAFIL POWDERMIX KIT versus NYSTEX.
NOXAFIL POWDERMIX KIT vs NYSTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Posaconazole inhibits fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and lead to leakage of intracellular contents and cell death.
300 mg (one 300-mg vial) intravenously twice on day 1, then 300 mg intravenously once daily starting on day 2. Alternatively, oral suspension: 200 mg (10 mL) three times daily. For prophylaxis, IV: 300 mg twice on day 1, then 300 mg once daily; oral: 200 mg three times daily.
Topical: Apply thin layer to affected area twice daily. Oral suspension (nystatin): 500,000-1,000,000 units (5-10 mL) four times daily for candidiasis. Vaginal tablets: 1 tablet (100,000 units) intravaginally once daily for 14 days.
None Documented
None Documented
The terminal elimination half-life is approximately 27 hours (range 20-66 hours) in healthy subjects, allowing for once-daily dosing after steady state.
Variable; estimated 2-5 hours for systemic absorption (if any), but negligible systemic levels due to poor absorption.
Posaconazole is primarily excreted in the feces (77%) as unchanged drug, with renal excretion accounting for 14% of the dose (primarily as glucuronide conjugates). Less than 0.2% is excreted unchanged in urine.
Primarily fecal (>95%) as unchanged drug; minimal renal excretion (<1%).
Category C
Category C
Antifungal
Antifungal